COX2 expression is associated with preoperative tumor volume but not with volumetric tumor growth in vestibular schwannoma
Tóm tắt
Vestibular schwannomas (VS) are benign slow growing tumors arising from the vestibular nerve. The role of cyclooxygenase 2 (COX2) in tumor development of growth has been addressed in a few studies with contradictory results and suggestions. We recently analyzed the immunohistochemical expression of COX2 in 1044 VS samples and described an association of higher COX2 expression with proliferation but found no influence by regular intake of acetylsalicylic acid. We now collected volumetric radiographic data of the preoperative tumor volume and growth to further test the role of COX2 in VS growth. Preoperative images of 898 primary sporadic vestibular schwannomas were assessed, and sufficient preoperative imaging was used for the volumetric measurement preoperative tumor volume (n = 747) and preoperative relative tumor growth (n = 171). Clinical parameters and results of the immunohistochemical expression of COX2 and MIB1 in resected tumor tissue samples were obtained from our prior study. ANOVA, CART-analysis and multivariate nominal logistic regression were used for statistical analysis. Larger preoperative tumor volumes were observed with tumors of younger patients (p = 0.0288) and with higher COX2 expression scores (p < 0.0001). Higher MIB1 expression was associated with smaller tumors (p = 0.0149) but with increased radiographic tumor growth (p = 0.0003). Patients of older age had tumors with slower growth rates (p = 0.0311). In the multivariate analysis only MIB1 expression was an independent significant factor regarding tumor growth (p = 0.0002). Higher expression of COX2 in schwannoma is associated with an increased preoperative tumor volume but not with radiographic tumor growth over time.
Tài liệu tham khảo
Behling, F., Ries, V., Skardelly, M., Gepfner-Tuma, I., Schuhmann, M., Ebner, F. H., … Tatagiba, M. (2019). COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake. Acta Neuropathologica Communications, 7(1), 105. https://doi.org/10.1186/s40478-019-0760-0.
Bi, W. L., Gupta, S., Mei, Y., Abdulmohsen, S. A., Giantini Larsen, A., Unadkat, P., … Dunn, I. F. (2020). Immunophenotype of vestibular Schwannomas. Otology & Neurotology, 41(10), e1290–e1296. https://doi.org/10.1097/MAO.0000000000002782.
Cao, Y., & Prescott, S. M. (2002). Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. Journal of Cellular Physiology, 190(3), 279–286. https://doi.org/10.1002/jcp.10068.
de Vries, W. M., Briaire-de Bruijn, I. H., van Benthem, P. P. G., van der Mey, A. G. L., & Hogendoorn, P. C. W. (2019). M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma. Virchows Archiv, 474(3), 375–381. https://doi.org/10.1007/s00428-018-2503-1.
Dilwali, S., Kao, S. Y., Fujita, T., Landegger, L. D., & Stankovic, K. M. (2015). Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Translational Research, 166(1), 1–11. https://doi.org/10.1016/j.trsl.2014.12.007.
Gao, C. F., Xie, Q., Su, Y. L., Koeman, J., Khoo, S. K., Gustafson, M., … Vande Woude, G. F. (2005). Proliferation and invasion: Plasticity in tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 102(30), 10528–10533. https://doi.org/10.1073/pnas.0504367102.
Hannan, C. J., Lewis, D., O'Leary, C., Donofrio, C. A., Evans, D. G., Roncaroli, F., … Pathmanaban, O. N. (2020). The inflammatory microenvironment in vestibular schwannoma. Neurooncol Adv, 2(1), vdaa023. https://doi.org/10.1093/noajnl/vdaa023.
Harder, A., Wesemann, M., Hagel, C., Schittenhelm, J., Fischer, S., Tatagiba, M., … Paulus, W. (2012). Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. The American Journal of Surgical Pathology, 36(5), 702–709. https://doi.org/10.1097/PAS.0b013e31824d3155.
Helbing, D. L., Schulz, A., & Morrison, H. (2020). Pathomechanisms in schwannoma development and progression. Oncogene, 39(32), 5421–5429. https://doi.org/10.1038/s41388-020-1374-5.
Hong, B., Krusche, C. A., Schwabe, K., Friedrich, S., Klein, R., Krauss, J. K., & Nakamura, M. (2011). Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas. Neurosurgery, 68(4), 1112–1117. https://doi.org/10.1227/NEU.0b013e318208f5c7.
Hunter, J. B., O'Connell, B. P., Wanna, G. B., Bennett, M. L., Rivas, A., Thompson, R. C., & Haynes, D. S. (2017). Vestibular Schwannoma growth with aspirin and other nonsteroidal anti-inflammatory drugs. Otology & Neurotology, 38(8), 1158–1164. https://doi.org/10.1097/MAO.0000000000001506.
Kandathil, C. K., Cunnane, M. E., McKenna, M. J., Curtin, H. D., & Stankovic, K. M. (2016). Correlation between aspirin intake and reduced growth of human vestibular Schwannoma: Volumetric analysis. Otology & Neurotology, 37(9), 1428–1434. https://doi.org/10.1097/MAO.0000000000001180.
Li, S., Jiang, M., Wang, L., & Yu, S. (2020). Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. Biomedicine & Pharmacotherapy, 129, 110389. https://doi.org/10.1016/j.biopha.2020.110389.
Lu, V. M., Ravindran, K., Graffeo, C. S., Perry, A., Van Gompel, J. J., Daniels, D. J., & Link, M. J. (2019). Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: A systematic review and meta-analysis of treatment outcomes. Journal of Neuro-Oncology, 144(2), 239–248. https://doi.org/10.1007/s11060-019-03234-8.
Nair, S., Baldawa, S. S., Gopalakrishnan, C. V., Menon, G., Vikas, V., & Sudhir, J. B. (2016). Surgical outcome in cystic vestibular schwannomas. Asian Journal Neurosurgery, 11(3), 219–225. https://doi.org/10.4103/1793-5482.145359.
Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2020). CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro-Oncology, 22(12 Suppl 2), iv1-iv96. doi:https://doi.org/10.1093/neuonc/noaa200
Park, S. J., Yang, N. R., & Seo, E. K. (2015). Vestibular schwannoma atypically invading temporal bone. Journal of Korean Neurosurgical Association, 57(4), 292–294. https://doi.org/10.3340/jkns.2015.57.4.292.
Plotkin, S. R., Duda, D. G., Muzikansky, A., Allen, J., Blakeley, J., Rosser, T., … Karajannis, M. A. (2019). Multicenter, prospective, phase II and biomarker study of high-dose Bevacizumab as induction therapy in patients with Neurofibromatosis type 2 and progressive vestibular Schwannoma. Journal of Clinical Oncology, 37(35), 3446–3454. https://doi.org/10.1200/JCO.19.01367.
Rizk, A. R., Adam, A., Gugel, I., Schittenhelm, J., Tatagiba, M., & Ebner, F. H. (2017). Implications of vestibular Schwannoma consistency: Analysis of 140 cases regarding radiologic and clinical features. World Neurosurgery, 99, 159–163. https://doi.org/10.1016/j.wneu.2016.11.082.
Toloczko-Iwaniuk, N., Dziemianczyk-Pakiela, D., Nowaszewska, B. K., Celinska-Janowicz, K., & Miltyk, W. (2019). Celecoxib in Cancer therapy and prevention - review. Current Drug Targets, 20(3), 302–315. https://doi.org/10.2174/1389450119666180803121737.
Van Gompel, J. J., Agazzi, S., Carlson, M. L., Adewumi, D. A., Hadjipanayis, C. G., Uhm, J. H., & Olson, J. J. (2018). Congress of Neurological Surgeons systematic review and evidence-based guidelines on emerging therapies for the treatment of patients with vestibular Schwannomas. Neurosurgery, 82(2), E52–E54. https://doi.org/10.1093/neuros/nyx516.
Xu, X. C. (2002). COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs, 13(2), 127–137. https://doi.org/10.1097/00001813-200202000-00003.